Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)
NCT03446612 · GlaxoSmithKline · PHASE2 · terminated · last registry update 2024-03-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study is terminated due to feasibility in recruitment.” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGLN2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-26Results posted on the registry: The University of Texas Health Science Center, Houston, vadadustat + placebo (NCT04478071)
- 2025-01-15Results posted on the registry: Akebia Therapeutics, Vadadustat + Mircera® (NCT04707768)
- 2025-01-13Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Roxadustat (NCT06772272)
- 2024-08-01Results posted on the registry: Kyntra Bio, Roxadustat + Placebo (NCT03263091)
- 2024-08-01Also stopped (terminated): Kyntra Bio, Roxadustat + Placebo (NCT03263091)
- 2024-07-25Phase 3 first posted: USRC Kidney Research, Vadadustat + Erythropoiesis Stimulating Agent (NCT06520826)
- 2024-04-22Results posted on the registry: AstraZeneca, Roxadustat + rHuEPO (NCT04655027)
- 2023-08-01Phase 3 first posted: Astellas Pharma Global Development, Inc., Roxadustat (NCT05970172)
- 2023-07-25Results posted on the registry: GlaxoSmithKline, Daprodustat + rhEPO (NCT03457701)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision